3. Umbruch 4.4..2005 - Online Pot

162 S.M. Huang and J.M. Walker
76 Monhemius R, Azami J, Green DL, Roberts MH (2001) CB1 receptor mediated analgesia from
the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic
pain. Brain Res 908: 67–74
77 Helyes Z, Nemeth J, Than M, Bolcskei K, Pinter E, Szolcsanyi J (2003) Inhibitory effect of anandamide
on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia
in the rat. Life Sci 73: 2345–2353
78 Hama AT, Urban MO (2004) Antihyperalgesic effect of the cannabinoid agonist WIN55,212-2 is
mediated through an interaction with spinal metabotropic glutamate-5 receptors in rats. Neurosci
Lett 358: 21–24
79 De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H, Mauler F (2004)
3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY
59-3074): a novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and antiallodynic
effects. J Pharmacol Exp Ther 310: 620–632
80 Dogrul A, Gul H, Yildiz O, Bilgin F, Guzeldemir ME (2004) Cannabinoids blocks tactile allodynia
in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 368: 82–86
81 Sim LJ, Selley DE, Childers SR (1995) In vitro autoradiography of receptor-activated G proteins
in rat brain by agonist-stimulated guanylyl 5'-[gamma-[ 35 S]thio]-triphosphate binding. Proc Natl
Acad Sci USA 92: 7242–7246
82 Breivogel CS, Sim LJ, Childers SR (1997) Regional differences in cannabinoid receptor/G-protein
coupling in rat brain. J Pharmacol Exp Ther 282: 1632–1642
83 Prather PL, Martin NA, Breivogel CS, Childers SR (2000) Activation of cannabinoid receptors in
rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different
potencies. Mol Pharmacol 57: 1000–1010
84 Houston DB, Howlett AC (1998) Differential receptor-G-protein coupling evoked by dissimilar
cannabinoid receptor agonists. Cell Signal 10: 667–674
85 Glass M, Northup JK (1999) Agonist selective regulation of G proteins by cannabinoid CB(1) and
CB(2) receptors. Mol Pharmacol 56: 1362–1369
86 Mukhopadhyay S, Howlett AC (2001) CB1 receptor-G protein association. Subtype selectivity is
determined by distinct intracellular domains. Eur J Biochem 268: 499–505
87 Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz J (2002) The
endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic
aspects. Pharmacol Ther 95: 137–152
88 Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K (1999) The neurobiology
of cannabinoid analgesia. Life Sci 65: 665–673
89 Hohmann AG (2002) Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral,
neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121: 173–190
90 Burstein SH, Friderichs E, Kogel B, Schneider J, Selve N (1998) Analgesic effects of 1',1'
dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice. Life Sci 63: 161–168
91 Burstein SH, Karst M, Schneider U, Zurier RB (2004) Ajulemic acid: A novel cannabinoid produces
analgesia without a “high”. Life Sci 75: 1513–1522
92 Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M (2004) A novel synthetic,
nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine
collagen-induced arthritis. Arthritis Rheum 50: 985–998
93 Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic
cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290:
1757–1762
94 Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid
receptor agonist. Biochem Pharmacol 46: 791–796
95 Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization
of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83–87
96 Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L (1998) The novel endogenous
cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections
with anandamide. Biochem J 331: 15–19
97 Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros
TJ, Krey JF, Chu CJ et al. (2002) An endogenous capsaicin-like substance with high potency at
recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99: 8400–8405
98 Egertová M, Cravatt BF, Elphick MR (2003) Comparative analysis of fatty acid amide hydrolase
and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for